Literature DB >> 11911442

The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression.

S Fuke1, S Suo, N Takahashi, H Koike, N Sasagawa, S Ishiura.   

Abstract

The human dopamine transporter (DAT1) gene contains a variable number of tandem repeats (VNTR) in its 3'-untranslated region (UTR). The linkage and association between the VNTR polymorphism of DAT1 and various neuropsychiatric disorders have been reported. We have determined the genomic structure of DAT1 genes containing 7-, 9-, 10-, and 11-repeat alleles and examined the effect of VNTR polymorphism in the 3'-UTR region of DAT1 on gene expression using the luciferase reporter system in COS-7 cells. Luciferase expression was significantly higher when the 3'-UTR of the DAT1 gene contained the 10-repeat allele than when it contained the 7- or 9-repeat alleles. This suggests that VNTR polymorphism affects the expression of the dopamine transporter.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11911442     DOI: 10.1038/sj.tpj.6500026

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  140 in total

1.  Effect of dopamine transporter genotype on intrinsic functional connectivity depends on cognitive state.

Authors:  Evan M Gordon; Melanie Stollstorff; Joseph M Devaney; Stephanie Bean; Chandan J Vaidya
Journal:  Cereb Cortex       Date:  2011-11-02       Impact factor: 5.357

2.  Additive effects of the dopamine D2 receptor and dopamine transporter genes on the error-related negativity in young children.

Authors:  A Meyer; D N Klein; D C Torpey; A J Kujawa; E P Hayden; H I Sheikh; S M Singh; G Hajcak
Journal:  Genes Brain Behav       Date:  2012-06-28       Impact factor: 3.449

Review 3.  Pharmacogenetics of antidepressant response.

Authors:  Stefano Porcelli; Antonio Drago; Chiara Fabbri; Sara Gibiino; Raffaella Calati; Alessandro Serretti
Journal:  J Psychiatry Neurosci       Date:  2011-03       Impact factor: 6.186

Review 4.  Genetic Similarities between Compulsive Overeating and Addiction Phenotypes: A Case for "Food Addiction"?

Authors:  Nina Carlier; Victoria S Marshe; Jana Cmorejova; Caroline Davis; Daniel J Müller
Journal:  Curr Psychiatry Rep       Date:  2015-12       Impact factor: 5.285

5.  Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues.

Authors:  Joseph P Schacht; Raymond F Anton; Konstantin E Voronin; Patrick K Randall; Xingbao Li; Scott Henderson; Hugh Myrick
Journal:  Neuropsychopharmacology       Date:  2012-10-03       Impact factor: 7.853

Review 6.  Symbiotic relationship of pharmacogenetics and drugs of abuse.

Authors:  Joni L Rutter
Journal:  AAPS J       Date:  2006-03-24       Impact factor: 4.009

7.  Association of dopamine transporter gene variants with childhood ADHD features in bipolar disorder.

Authors:  Tiffany A Greenwood; Eun-Jeong Joo; Tatyana Shekhtman; A Dessa Sadovnick; Ronald A Remick; Paul E Keck; Susan L McElroy; John R Kelsoe
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2012-12-19       Impact factor: 3.568

8.  Dopamine transporter (DAT1) VNTR polymorphism in 12 Indian populations.

Authors:  L V K S Bhaskar; Kumarasamy Thangaraj; Connie J Mulligan; Samiksha Wasnik; Amrita Nandan; Varun Kumar Sharma; Vishwas Sharma; Alla Govardhana Reddy; Lalji Singh; Vadlamudi Raghavendra Rao
Journal:  Neurol Sci       Date:  2009-09-25       Impact factor: 3.307

9.  The impact of genetic variation in DRD2 and SLC6A3 on smoking cessation in a cohort of participants 1 year after enrollment in a lung cancer screening study.

Authors:  Mindi A Styn; Tomoko Nukui; Marjorie Romkes; Kenneth Perkins; Stephanie R Land; Joel L Weissfeld
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2009-03-05       Impact factor: 3.568

10.  Born to Lead? A Twin Design and Genetic Association Study of Leadership Role Occupancy.

Authors:  Jan-Emmanuel De Neve; Slava Mikhaylov; Christopher T Dawes; Nicholas A Christakis; James H Fowler
Journal:  Leadersh Q       Date:  2012-09-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.